South Korea Real World Evidence Solutions Market Size is Expected to Grow from USD 18.4 Million in 2024 to USD 62.5 Million by 2035, Growing at a CAGR of 11.76% during the forecast period 2025-2035.

South Korea Real World Evidence Solutions Market Insights Forecasts to 2035

• The South Korea Real World Evidence Solutions Market Size Was Estimated at USD 18.4 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 11.76% from 2025 to 2035
• The South Korea Real World Evidence Solutions Market Size is Expected to Reach USD 62.5 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Real World Evidence Solutions Market Size is anticipated to reach USD 62.5 Million by 2035, Growing at a CAGR of 11.76% from 2025 to 2035. Post-approval safety surveillance investigations have been supported by RWE solutions on a large scale. The efficacy of medications, international authorities have recently begun incorporating RWE solutions into the early stages of drug development and various stages of the drug life cycle. Numerous nations use RWE systems for post-marketing efficacy evaluation and pharmacovigilance initiatives.

Market Overview

The market for technology and services that use real-world data (RWD) to produce clinical insights on medical products, therapies, and healthcare interventions is known as the real-world evidence (RWE) solutions market. The determine the genuine impact of these interventions, RWE solutions evaluate their performance in real-world situations, taking into account variables such as patient adherence and comorbidities. RWE facilitates quicker decision-making during clinical trials by offering real-time insights into patient outcomes and treatment patterns, which speeds up drug development. By identifying suitable patient populations and streamlining data gathering, RWE can assist in lowering the cost of clinical studies. The demand for RWE to comprehend treatment efficacy and patient outcomes is driven by the rising incidence of chronic illnesses like cancer and cardiovascular disorders. Create and apply RWE approaches, government programs promote cooperation between industry, academic institutions, and regulatory bodies.

Report Coverage

This research report categorizes the market for South Korea real world evidence solutions market based on various segments and regions forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea real world evidence solutions market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea real world evidence solutions market.

Driving Factors

The increasing prevalence of chronic diseases and the aging global population are propelling the demand for innovative healthcare solutions. RWE enables healthcare providers to assess treatment outcomes in real-world settings, facilitating personalized and evidence-based care. Additionally, the shift towards value-based care models emphasizes the need for cost-effective and patient-centered approaches, further accelerating the adoption of RWE solutions. Technological advancements, such as the integration of artificial intelligence and big data analytics, are enhancing the capabilities of RWE platforms, enabling more accurate and timely insights.

Restraining Factors

A significant hurdle is the lack of standardized methodologies for data collection, analysis, and reporting, leading to inconsistent data quality and limited comparability. Additionally, stringent data privacy regulations, such as the GDPR and HIPAA, impose compliance burdens, especially when handling sensitive health information across borders.

Market Segmentation

The South Korea real world evidence solutions market share is classified into component, application, end-use, and therapeutic area.

• The services segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea real world evidence solutions market is segmented by component into services and data sets. Among these, the services segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. The market's expansion is ascribed to the widespread use of real-world services by biotechnology and pharmaceutical firms as well as healthcare providers. Over the course of the projected period, the segment is also expected to record the fastest CAGR.

• The drug development segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea real world evidence solutions market is segmented by application into drug development and approvals. Among these, the drug development segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Pharmaceutical companies, healthcare providers, and payers can manage their operations more effectively and expedite the medication research and approval process with the use of real-world evidence solutions.

• The healthcare companies segment dominated share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea real world evidence solutions market is segmented by end-use into healthcare companies and healthcare payers. Among these, the healthcare companies segment dominated share in 2024 and is expected to grow at a significant CAGR during the forecast period. The need to prevent costly drug recalls the growing importance of RWE studies in drug approvals, and the growing requirement to assess drug efficacy in real-world situations are all factors contributing to the growth.

• The oncology segment held a majority share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea real world evidence solutions market is segmented by therapeutic area into oncology and cardiology. Among these, the oncology segment held a majority share in 2024 and is expected to grow at a significant CAGR during the forecast period. RWE solutions have a number of uses in the development of cancer drugs, including lowering clinical trial costs, enhancing the likelihood of regulatory success, and accelerating product approval rates.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea real world evidence solutions market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies                                            

• Lunit
• AITRICS
• Life Semantics
• Deep Bio
• KaiPharm
• JNPMEDI
• Mediwhale
• LegoChem Biosciences
• D&D Pharmatech
• Standigm
• Genome & Company
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea real world evidence solutions market based on the below-mentioned segments:

 South Korea Real World Evidence Solutions Market, By Component

• Services
• Data Sets

South Korea Real World Evidence Solutions Market, By Application

• Drug Development
• Approvals

South Korea Real World Evidence Solutions Market, By End-use

• Healthcare Companies
• Healthcare Payers

South Korea Real World Evidence Solutions Market, By Therapeutic Area

• Oncology
• Cardiology